Kedrion donates 1 million IU of FIX to support WHF Humanitarian Aid Program
The aim is to broaden access to haemophilia treatment regardless of the patients’ geographical location.
Grifols transfers to Kedrion the management of the plasma fractionation plant of Melville (USA), owned by Kedrion
Kedrion announces that, effective 1st July, 2013, Grifols S.A. will complete the transfer to Kedrion of all the operations for managing the plasma fractionation plant of Melville, State of New York (USA), owned by Kedrion. This action is part of the agreements entered into in 2011, included in the Consent Agreement of the Federal Trade
Kedrion reinforces its presence in the United States. Agreement with US-bades OCD for the acquisition of one of the company’s branches
Kedrion reinforces its presence in the United States. The company, based in Castelvecchio Pascoli (Lucca), acquired from Ortho-Clinical Diagnostics, Inc. (OCD) the branch specialising in the production of human anti-D immunoglobulin, an effective product for the prevention of the “haemolytic disease of the newborn” (HDN), a condition that occurs in Rh-positive foetuses and new-born babies
Italian Strategic Fund invests in Kedrion
Fondo Strategico Italiano (FSI), the Italian Strategic Fund, has become a joint owner of Kedrion with an overall financial contribution of 150 million euros (75 million euros in capital increase and 75 million euros in a convertible or reimbursable line of credit). The company’s ownership will be divided as follows: 48.8 per cent to the
Kedrion reinforces its presence in the US. Closed acquisition of Grifols’ assets. Incorporation of the new Kedrion Biopharma
Kedrion, a biopharmaceutical company specialising in the development, production and distribution of plasma-derived medicinal products, announces that, having received the approval from the US Federal Trade Commission (FTC), it has finalized the transaction previously announced on May 2nd relative to the purchase of certain assets from Grifols S.A. and the commercial and manufacturing agreement between
Agreements between Kedrion and Grifols
Kedrion announces today to have reached an agreement with Grifols S.A. (Grifols) for the sale of Grifols’ assets to Kedrion; the two companies also have established commercial, lease and manufacturing agreements for up to seven (7) years. This agreement has been reached in order to satisfy the conditions for the merger transaction between Grifols and
Fondazione Toscana Life Sciences grants Kedrion a line for small productions at the Tech Park in Siena
Fondazione Toscana Life Sciences, a non-profit organisation specialising in the establishment of new pharmaceutical/biotechnological ventures, and Kedrion, a biopharmaceutical company specialising in the development and manufacture of plasma-derived products, announced they have entered into an agreement under which Kedrion will be granted a biopharmaceutical production laboratory in accordance with the GMPs – Good Manufacturing Practices,
BioSC, Kedrion’s excellence in the new Biological Safety Centre for viral validation studies
The Biological Safety Centre – BioSC, specialized in viral validation studies, more specifically “studies for inactivation/removal of viral and non-viral pathogens (prions) for biological and biotechnological productions” for in-house and outsourced services, has been opened. BioSC’s mission is to respond with full capabilities to the current and future requirements in terms of safety from biological
Kedrion S.p.A. Board of Directors approves 2009 financial statements
The Board of Directors of Kedrion SpA – specialising in the development, manufacture and distribution of plasma derived medicinal products, led by Paolo Marcucci, President and CEO – met today to approve the 2009 Financial Statements. In the financial year 2009, Kedrion Group achieved some major results, despite the challenging scenario, retaining its leading position
Growth of the Kedrion Group: expansion of the Hungarian plant starting now. A new Plasmaphereris centre settled in Budapest
Kedrion Group’s growth strategy is progressing in two directions: one is the vertical integration of its operations, the other is the expansion of its production capacity aimed at consolidating its international market share, especially in Europe. The start of the upgrading and expansion of the Gödöllo plant, commissioned to the Engineering Company Foster Wheeler Italiana